Nuvasive Inc (NUVA): Jason Hannon , EVP, International of Nuvasive Inc sold 14,534 shares on Jun 15, 2016. The Insider selling transaction was reported by the company on Jun 17, 2016 to the Securities and Exchange Commission. The shares were sold at $57.92 per share for a total value of $836,773.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 7, 2016, Patrick Miles (President and COO) sold 10,723 shares at $54.41 per share price.On Dec 7, 2015, Quentin S. Blackford (CFO and CAO) sold 15,000 shares at $51.10 per share price.Also, On Oct 5, 2015, Matthew Link (President, U.S. Commercial) sold 1,714 shares at $50.72 per share price.On Sep 10, 2015, Russell Powers (EVP) sold 5,806 shares at $51.64 per share price.
Shares of NuVasive (NUVA) ended Wednesday, Jun 15, 2016 session in red amid volatile trading. The shares closed down -0.39 points or -0.67% at $57.69 with 8,63,266 shares getting traded. Post opening the session at $58.42, the shares hit an intraday low of $57.45 and an intraday high of $58.59 and the price vacillated in this range throughout the day. The company has a market cap of $2,875 M and the number of outstanding shares has been calculated to be 4,98,33,030 shares. The 52-week high of NuVasive is $60.09 and the 52-week low is $36.81.
Company has been under the radar of several Street Analysts.NuVasive is Upgraded by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 63 from a previous price target of $58 .Earlier the firm had a rating of Equal Weight on the company shares. The Rating was issued on May 27, 2016.
Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.